RL
RLAY.US Relay Therapeutics Inc
- Market cap
- USD 3.64B
- P/E
- -
- P/B
- 4.66x
- ROE
- -38.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RLAY.US undervalued?
Graham numberThe Graham number of Relay Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Relay Therapeutics Inc fundamental analysis
No fundamental analysis for Relay Therapeutics Inc yet.
Relay Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular m…
Full company profileRelay Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Relay Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 82.7M | 3.03M | 1.38M | 25.5M | 10.0M | 15.4M | 4.47M |
| Gross Profit | -2.15M | -2.85M | 79.1M | -166M | -242M | -301M | -305M | 11.8M | - |
| Operating Income | -49.9M | -84.0M | -55.8M | -365M | -299M | -373M | -372M | -303M | -346M |
| EBITDA | -47.7M | -81.2M | -52.2M | -223M | -307M | -374M | -380M | -273M | -317M |
| Net Income | -48.8M | -66.5M | -52.4M | -364M | -291M | -342M | -338M | -276M | -318M |
| EPS | -20 | -16 | -0.58 | -3.82 | -2.59 | -2.79 | -2.36 | -1.61 | -1.45 |
| Balance Sheet | |||||||||
| Total Assets | 429M | 393M | 800M | 1.01B | 1.10B | 844M | 871M | 621M | 902M |
| Total Liabilities | 540M | 574M | 36.5M | 111M | 150M | 92.0M | 93.5M | 54.3M | 82.7M |
| Shareholders' Equity | -111M | -180M | 763M | 898M | 950M | 752M | 778M | 567M | 819M |
| Cash & Short-term Investments | 422M | 356M | 678M | 958M | 999M | 750M | 781M | 555M | 849M |
| Total Debt | 178K | 24.8M | 24.4M | 22.9M | 57.7M | 53.5M | 48.5M | 32.5M | 27.0M |
| Cash Flow | |||||||||
| Operating Cash Flow | -44.1M | -66.1M | -102M | -74.4M | -229M | -300M | -249M | -235M | -226M |
| Capital Expenditure | 1.69M | 8.00M | 1.93M | 3.47M | 9.06M | 4.13M | 2.02M | 410K | 0.00 |
| Free Cash Flow | -45.8M | -74.1M | -104M | -77.9M | -239M | -304M | -251M | -236M | -226M |
| Ratios | |||||||||
| ROE | - | - | -6.9% | -40.5% | -30.6% | -45.5% | -43.4% | -48.8% | -38.9% |
| ROA | -11.4% | -16.9% | -6.6% | -36.1% | -26.4% | -40.5% | -38.8% | -44.5% | -35.3% |
| Net Profit Margin | - | - | -63.4% | -12,012.9% | -21,036.1% | -1,338.7% | -3,374.7% | -1,800.6% | -7,126.7% |
| Debt to Equity | - | - | 0.03x | 0.03x | 0.06x | 0.07x | 0.06x | 0.06x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Relay Therapeutics Inc dividends
Relay Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Relay Therapeutics Inc
- Insiders 1.56%
- Institutions 98.44%
- Public & others 0.00%
- Shares outstanding 221M
- Free float 147M
Top funds holding RLAY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 6.84M | 3.09% | +0.32% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 5.22M | 2.36% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 4.62M | 2.09% | 0.00% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.62M | 1.18% | +34.63% | Sep 2026 |
| Fidelity Select Health Care | 2.08M | 0.94% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth | 1.92M | 0.87% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 1.85M | 0.84% | 0.00% | Sep 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 1.83M | 0.83% | 0.00% | Sep 2026 |
| Harbor Small Cap Growth Instl | 1.81M | 0.82% | +9.62% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 1.78M | 0.81% | +6.06% | Aug 2026 |
| Fidelity Small Cap Index | 1.77M | 0.80% | +0.14% | Aug 2026 |
| Polar Capital Biotech S Inc | 1.69M | 0.77% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 1.64M | 0.74% | 0.00% | Aug 2026 |
| T. Rowe Price Small-Cap Stock | 1.55M | 0.70% | +2.51% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 1.37M | 0.62% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 1.34M | 0.61% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 1.34M | 0.60% | -0.19% | Oct 2026 |
| T. Rowe Price Health Sciences | 1.28M | 0.58% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 1.28M | 0.58% | -11.03% | Sep 2026 |
| Pictet-Biotech P USD | 1.14M | 0.51% | +0.38% | Jul 2026 |
Top institutions holding RLAY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 27.9M | 12.63% | 0.00% | Jun 2026 |
| FMR Inc | 20.1M | 9.10% | +444.19% | Jun 2026 |
| Casdin Capital, LLC | 16.0M | 7.26% | +11.21% | Jun 2026 |
| BlackRock Inc | 15.3M | 6.92% | +17.83% | Jun 2026 |
| Perceptive Advisors LLC | 14.1M | 6.38% | +44.66% | Jun 2026 |
| COMMODORE CAPITAL LP | 12.0M | 5.43% | -29.41% | Jun 2026 |
| State Street Corp | 10.1M | 4.58% | +62.43% | Jun 2026 |
| Vanguard Capital Management, LLC | 8.96M | 4.06% | +21.35% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 7.71M | 3.49% | +300.45% | Jun 2026 |
| Nextech Invest, Ltd. | 6.78M | 3.07% | +22.62% | Jun 2026 |
| Bellevue Group AG | 6.19M | 2.80% | -20.64% | Jun 2026 |
| Geode Capital Management, LLC | 4.73M | 2.14% | +34.64% | Jun 2026 |
| TCG Crossover Management, LLC | 4.27M | 1.93% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 4.10M | 1.85% | +2,719.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.85M | 1.74% | +168.93% | Jun 2026 |
| Siren, L.L.C. | 3.65M | 1.65% | 0.00% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 3.61M | 1.64% | +8.08% | Sep 2026 |
| The Goldman Sachs Group Inc | 3.41M | 1.54% | +34.10% | Jun 2026 |
| Kynam Capital Management, LP | 3.30M | 1.49% | +131.70% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.18M | 1.44% | +1.56% | Sep 2026 |
Relay Therapeutics Inc company profile
- Company name
- Relay Therapeutics Inc
- Ticker
- RLAY.US
- Exchange
- USA Stocks
- Listed since
- Jul 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 218
- Fiscal year end
- December
- Address
- 60 Hampshire Street, Cambridge, MA, United States, 02139
- Phone
- 617 370 8837
- Website
- relaytx.com
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics Inc management
10- Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO, President & Director · born 1974
- Dr. Mark Murcko Ph.D.Founder & Independent Director · born 1960
- Mr. Thomas CatinazzoChief Financial Officer · born 1976
- Mr. Peter RahmerChief Corporate Development Officer · born 1982
- Dr. Donald A. Bergstrom M.D., Ph.D.President of Research & Development · born 1972
- Ms. Dorothee Kern Ph.D.Founder
- Dr. David Elliot Shaw Ph.D.Founder · born 1951
- Dr. Matthew P. Jacobson Ph.D.Founder
- Mr. Jim Watters Ph.D.Chief Scientific Officer
- Ms. Soo-Yeun Lim J.D.Senior VP & General Counsel